Bergenbio ASA Cash Flow Conversion Efficiency
Bergenbio ASA cash flow conversion efficiency. Based on the latest financial reports, Bergenbio ASA (BGBIO) has a cash flow conversion efficiency ratio of -1.249x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-153.24 Million ≈ $-16.13 Million USD) by net assets (Nkr122.70 Million ≈ $12.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bergenbio ASA (2014–2024)
Cash flow conversion efficiency of Bergenbio ASA from 2014 to 2024. This chart illustrates how Bergenbio ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bergenbio ASA stock price for real-time trading data and today's change.
Bergenbio ASA Cash Flow Conversion Ratio Explained
Bergenbio ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bergenbio ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bergenbio ASA ranked by their cash flow conversion efficiency. Also see Bergenbio ASA (BGBIO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mydas Real Estate Investments Ltd
TA:MYDS
|
-0.280x |
|
DIGIDRIVE DISTRIBUTORS LTD
NSE:DIGIDRIVE
|
-0.008x |
|
Nimy Resources Ltd
AU:NIM
|
-0.130x |
|
KWESST MICRO SYS.INC.
F:62UA
|
-0.430x |
|
Airway
WAR:AWM
|
-0.055x |
|
Caely Holdings Bhd
KLSE:7154
|
-0.006x |
|
Mitra Komunikasi Nusantara Tbk PT
JK:MKNT
|
-2.611x |
|
Moksh Ornaments Limited
NSE:MOKSH
|
-0.121x |
Annual Cash Flow Conversion Efficiency for Bergenbio ASA (2014–2024)
The table below shows the annual cash flow conversion efficiency of Bergenbio ASA from 2014 to 2024. Review BGBIO free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr122.70 Million ≈ $12.91 Million |
Nkr-153.24 Million ≈ $-16.13 Million |
-1.249x | +43.24% |
| 2023-12-31 | Nkr127.48 Million ≈ $13.41 Million |
Nkr-280.50 Million ≈ $-29.52 Million |
-2.200x | +32.44% |
| 2022-12-31 | Nkr88.50 Million ≈ $9.31 Million |
Nkr-288.23 Million ≈ $-30.33 Million |
-3.257x | -312.75% |
| 2021-12-31 | Nkr384.43 Million ≈ $40.45 Million |
Nkr-303.34 Million ≈ $-31.92 Million |
-0.789x | -125.73% |
| 2020-12-31 | Nkr670.23 Million ≈ $70.53 Million |
Nkr-234.29 Million ≈ $-24.65 Million |
-0.350x | +58.28% |
| 2019-12-31 | Nkr219.75 Million ≈ $23.12 Million |
Nkr-184.15 Million ≈ $-19.38 Million |
-0.838x | -51.38% |
| 2018-12-31 | Nkr337.28 Million ≈ $35.49 Million |
Nkr-186.71 Million ≈ $-19.65 Million |
-0.554x | -15.37% |
| 2017-12-31 | Nkr350.35 Million ≈ $36.87 Million |
Nkr-168.11 Million ≈ $-17.69 Million |
-0.480x | +40.84% |
| 2016-12-31 | Nkr153.27 Million ≈ $16.13 Million |
Nkr-124.31 Million ≈ $-13.08 Million |
-0.811x | +16.51% |
| 2015-12-31 | Nkr64.75 Million ≈ $6.81 Million |
Nkr-62.90 Million ≈ $-6.62 Million |
-0.972x | -155.71% |
| 2014-12-31 | Nkr141.38 Million ≈ $14.88 Million |
Nkr-53.72 Million ≈ $-5.65 Million |
-0.380x | -- |
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.